Article on lentiviral vector therapies in-vivo and ex-vivo in The Medicine Maker

Know Your Vectors: A Comprehensive Guide to In Vivo and Ex Vivo Lentiviral Therapies

As gene and cell therapies gain ground in clinical development, lentiviral vector therapies have emerged as a powerful tool for targeted genetic delivery. Whether applied in vivo or ex vivo, lentiviral vectors offer flexibility, efficiency, and long-term gene expression with relatively low pathogenicity. In this article, we provide a complete overview of how lentiviral vectors work, how they are manufactured and optimized, and their growing role in the future of gene-modified cell therapies.

The Rising Impact of Gene and Cell Therapy

As of mid-2022, over 2,000 gene and gene-modified-cell therapies were in development worldwide. The FDA expects to approve 10 to 20 cell and gene therapy products annually by 2025, and the sector is projected to reach $17.3 billion by 2035, with an estimated CAGR of 18% between 2022 and 2035. Among the technologies driving this revolution, lentiviral vector-based therapies are among the most promising.

What Are Lentiviral Vectors?

Lentiviral vectors are engineered viruses capable of delivering therapeutic genes into target cells. Unlike many other vectors, they can transduce both dividing and non-dividing cells, allowing for stable, long-term transgene expression. Their low immunogenicity and ability to integrate into the host genome make them particularly attractive for both ex vivo and in vivo gene therapy applications.

 In Vivo vs. Ex Vivo: Key Differences

• Ex vivo gene therapy involves removing patient cells, genetically modifying them in the lab, and reintroducing them into the body. Since only the target cells are exposed to the vector, broad-tropism pseudotypes like VSV-G are often used.
• In vivo gene therapy delivers vectors directly to the patient, requiring highly specific pseudotyping to avoid off-target effects. This method is particularly valuable when target cells cannot be isolated beforehand. However, it introduces additional challenges, such as the need for high vector titers and immune evasion strategies.

However, it introduces additional challenges, such as the need for high vector titers and immune evasion strategies.

To better understand these approaches, it is important to explore the concept of gene transfer and why in vivo strategies are gaining relevance.

Gene Transfer: The Foundation of Modern Therapies

Gene transfer is the process of introducing genetic material into cells to correct or modify their function. In the context of lentiviral vectors, this approach enables stable integration and long-term expression of therapeutic genes. Unlike other viral vectors, lentiviruses can target both dividing and non-dividing cell types, making them highly versatile for treatment of complex diseases.

In Vivo Gene Transfer and Its Advantages

In vivo gene transfer refers to delivering genetic material directly into the patient’s body. This method is essential when isolating cells ex vivo is not feasible. It requires precise targeting, high vector titers, and strategies to avoid immune detection, including the use of engineered envelopes. This is why in vivo approaches are increasingly considered for diseases where ex vivo manipulation is impractical or less efficient.

The Role of Pseudotyping in Vector Specificity

Pseudotyping involves replacing the envelope proteins of lentiviral vectors with those from other viruses to tailor their cell tropism. This technique enhances targeting specificity and infection efficiency, especially when working with hard-to-transduce cells like NK cells or hematopoietic stem cells, which express low levels of VSV-G receptors.

Inside the Manufacturing Process

The most commonly used producer cell line is HEK293, which is transfected with a series of plasmids that encode the viral components. The envelope protein is provided in trans to reduce recombination risks and improve biosafety. The more plasmids used, the safer the system due to lower chances of recombination.

For in vivo applications, production must be scaled up significantly. This includes not only upstream improvements in vector yield but also optimized downstream processing, such as ultrafiltration, to concentrate viruses without damaging their functionality.

Real-World Applications: From CAR-T to Ophthalmology

One of the most successful examples of ex vivo therapy is CAR-T therapy, where T cells are engineered to recognize and attack cancer cells. This approach is expected to grow into a $21 billion market by 2030.

In the in vivo space, lentiviral vectors are being developed for delivery via the portal vein (liver), ocular injections (retina), and systemic routes, depending on the disease and target tissue.

Innovation & Customization

Some biotech partners go one step further by using their own custom packaging cell lines. This allows lentivectors to be “masked” for better immune evasion or to carry unique surface markers for more refined targeting.

Future Outlook

With the continuous refinement of pseudotyping strategies, bioreactor scalability, and vector engineering, lentiviral vector therapies are poised to play a central role in the next generation of gene-modified cell therapies. Whether administered ex vivo or in vivo, they offer a flexible and increasingly safe solution for a wide range of genetic diseases.

Extended Insights: Key Technical Considerations

• Lentivirus in vivo and in vivo Gene Therapy

The term lentivirus in vivo refers to direct administration of vectors into the patient. This approach is essential for in vivo gene therapy, where target cells cannot be extracted for modification.

• Transgene Expression and Viral Genome

Efficient transgene expression depends on vector design and the stability of the viral genome.

• In vivo Transduction and Antibody Response

In vivo transduction can be limited by immune responses. Neutralizing antibodies and pre-existing immunity are major challenges for systemic delivery.

• Manufacture and Quality Control

Scaling up manufacture for clinical-grade vectors requires strict quality control to ensure safety and potency.

• In vivo Lentiviruses and Safety

Only replication-deficient forms of lentiviral vectors are used to minimize risk.

Key Takeaways

• Lentiviral vectors can be used in vivo and ex vivo.
• Pseudotyping enables cell-specific targeting and boosts efficiency.
• HEK293 cells are the most common vector producers.
• In vivo therapies require large vector quantities and precise downstream optimization.
• CAR-T therapy is a notable ex vivo success, while liver and eye-directed therapies show promise in vivo.
• Custom packaging systems are emerging to reduce immunogenicity.

You can read the full article here: https://www.themedicinemaker.com/issues/2022/articles/dec/know-your-vectors-a-101-on-lentiviral-therapies/